#Sweden #Stockholm #Sobi #Altuvoct #Gamifant

Sobi's Q2 2026 Report: Major Growth and Pipeline Developments

On July 16, 2026, Swedish Orphan Biovitrum AB, commonly known as Sobi®, released its report for the second quarter of the year. The results indicate impressive growth and significant progress in their product pipeline, sending waves of optimism through the biopharmaceutical community.

Financial Highlights

Sobi’s total revenue surged by an astonishing 29% at constant exchange rates (CER), and 27% on actual rates, hitting SEK 7,842 million compared to SEK 6,175 million in the same quarter last year. This remarkable increase can be primarily attributed to robust sales in two key therapeutic areas: haematology and immunology.

Haematology Growth

The haematology segment achieved a remarkable revenue increase of 27% at CER, totaling SEK 5,726 million, up from SEK 4,570 million. Key drivers included the outstanding performance of two products: Altuvoct, generating SEK 1,554 million in revenues compared to SEK 627 million the previous year, and Doptelet, which recorded revenues of SEK 1,628 million, up from SEK 1,220 million. This strong growth signal reflects Sobi's commitment to meeting the needs of patients with rare bleeding disorders, where effective therapies remain critically important.

Immunology Performance

In the immunology sector, Sobi reported impressive growth with a 37% increase at CER, bringing in SEK 1,711 million, compared to SEK 1,288 million in Q2 of the previous year. The company's immunology portfolio was bolstered by Gamifant, which generated SEK 794 million in sales, up from SEK 632 million, and Kineret, which recorded sales of SEK 861 million, compared to SEK 749 million last year. This growth underscores Sobi’s effective strategies in targeting complex conditions associated with autoimmune diseases.

Strategic Portfolio Expansion

Revenue from Sobi's strategic portfolio showcased an astounding growth of 53% at CER, reaching SEK 5,095 million from SEK 3,384 million. This growth is indicative of the company’s successful strategies in expanding its product offerings and enhancing market presence.

Profitability Metrics

The adjusted EBITA margin saw a slight increase to 35% from the previous 34%. Adjusted EBITA rose significantly to SEK 2,843 million, reflecting continuous operational efficiencies and robust sales performance. Earnings per share (EPS) before dilution also improved to SEK 3.17 from SEK 1.85. Notably, adjusted EPS before dilution increased to SEK 4.00, compared to SEK 2.38 from the same period last year.

Cash Flow and Future Outlook

Sobi generated cash flow from operating activities amounting to SEK 1,912 million, an increase from SEK 1,448 million. Looking ahead, Sobi anticipates revenue growth in the mid-to-high teens at CER for the remaining year, a revision from earlier expectations of low double-digit growth. The adjusted EBITA margin is also projected to remain in the mid-to-high 30s percentage of revenue.

Pipeline Progress

Furthermore, the report addressed recent advancements in Sobi’s pipeline. A Complete Response Letter (CRL) has been received concerning manufacturing, with plans for resubmission aimed at potential treatment for uncontrolled gout. Encouragingly, Pozdeutinurad demonstrated positive topline results from the pivotal Phase 3 REDUCE 2 study in gout, marking another milestone in Sobi's ongoing efforts to treat rare diseases.

Conclusion

This quarter has proven to be a vital period for Sobi, reflecting not only strong financial performance but also significant advancements in product offerings. As the company moves forward, its strong action plan and commitment to innovation are expected to maintain its upward trajectory in the biopharmaceutical market. For further details, investors and interested parties are invited to participate in today's upcoming conference call, where the management team will delve into the results and answer any questions regarding the quarterly performance. The future looks promising for Sobi as it continues to transform lives through cutting-edge therapies.